Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Cornen, Stéphanie ^a   Guille, Arnaud ^a   Adélaïde, José ^a   Addou Klouche, Lynda ^a,b   Finetti, Pascal ^a   Saade, Marie Rose ^a   Manai, Marwa ^a,c   Carbuccia, Nadine ^a   Bekhouche, Ismahane ^a   Letessier, Anne ^a   Raynaud, Stéphane ^a   Charafe Jauffret, Emmanuelle ^a,d   Jacquemier, Jocelyne ^a   Spicuglia, Salvatore ^d,e   De The, Hugues ^f   Viens, Patrice ^a,d   Bertucci, François ^a,d   Birnbaum, Daniel ^a   Chaffanet, Max ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b UNIVERSITY OF SIDI BEL ABBES   (Algeria)

^c FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^d AIX MARSEILLE UNIVERSITY   (France)

^e Aix Marseille university   (France)

^f Institut Universitaire d'Hématologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR FKHRL1;

ADULT; ARTICLE; BREAST CANCER; CHROMOSOME 6Q; COPY NUMBER ABERRATION; COPY NUMBER VARIATION; DISEASE COURSE; DNA METHYLATION; FEMALE; FOXO3 GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENOME; HORMONE RESISTANCE; HUMAN; HUMAN TISSUE; KCNB2 GENE; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; MDN1 GENE; ONCOGENE; PATHOGENESIS; PIK3CA GENE; SOMATIC MUTATION; TP53 GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE; UTRN GENE;

BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 6; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENETIC ASSOCIATION STUDIES; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KAPLAN-MEIER ESTIMATE; META-ANALYSIS AS TOPIC; MULTIVARIATE ANALYSIS; MUTATION; PROMOTER REGIONS, GENETIC; RECQ HELICASES; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER;

EID: 84897498801     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081843     Document Type: Article

References (68)

1. Dunn L, Demichele A (2009) Genomic predictors of outcome and treatment response in breast cancer. Mol Diagn Ther 13: 73-90.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
3. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874. (Pubitemid 32878711)
4. Hu Z, Fan C, Oh DS, Marron JS, He X, et al. (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96.
5. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360: 790-800.
6. Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, et al. (2005) Comprehensive profiling of 8p11-12 amplification in breast cancer. Molecular Cancer Research 3: 655-667. (Pubitemid 43042995)
7. Bergamaschi A, Kim YH, Wang P, Sørlie T, Hernandez-Boussard T, et al. (2006) Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45: 1033-1040. (Pubitemid 44435537)
8. Andre F, Job B, Dessen P, Tordai A, Michiels S, et al. (2009) Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 15: 441-451.
9. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, et al. (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529-541. (Pubitemid 44854748)
10. Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, de Medina SG, et al. (2006) Regional copy number-independent deregulation of transcription in cancer. Nat Genet 38: 1386-1396. (Pubitemid 44837560)
11. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527. (Pubitemid 44854747)
12. Adélaïde J, Finetti P, Bekhouche I, Repellini L, Geneix J, et al. (2007) Integrated profiling of basal and luminal breast cancers. Cancer Res 67: 11565-11575.
13. Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, et al. (2007) High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol 8: R215.
14. Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, et al. (2008) breast cancer study group of the Institut Curie. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res14:1956-1965. (Pubitemid 351551104)
15. Addou-Klouche L, Adélaïde J, Finetti P, Carbuccia N, Ferrari A, et al. (2010) Loss, mutation and deregulation of L3MBTL4 in breast cancers. Mol Cancer 9: 213.
16. Horlings HM, Lai C, Nuyten DS, Halfwerk H, Kristel P, et al. (2010) Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients. Clin Cancer Res 16: 651-663.
17. Sircoulomb F, Bekhouche I, Finetti P, Adélaïde J, Ben Hamida A, et al. (2010) Genome profiling of ERBB2-amplified breast cancers. BMC Cancer 10: 539.
18. Bekhouche I, Finetti P, Adélaïde J, Ferrari A, Tarpin C, et al. (2011) High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes. PLoS ONE 6: e16950.
19. Sircoulomb F, Nicolas N, Ferrari A, Finetti P, Bekhouche I, Rousselet E, et al. (2011) ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med 3: 153-166.
20. Bediaga NG, Acha-Sagredo A, Guerra I, Viguri A, Albaina C, et al. (2010) DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res 12: R77.
21. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jönsson G, et al. (2010) Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 12: R36.
22. van der Auwera I, Yu W, Suo L, Van Neste L, van Dam P, et al. (2010) Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS One 5: e12616-12625.
23. Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, et al. (2011) Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 71: 6195-6207.
24. Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, et al. (2010) Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res 71: 2988-2999.
25. Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, et al. (2011) Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol 12: R6.
26. Ha KC, Lalonde E, Li L, Cavallone L, Natrajan R, et al. (2011) Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines. BMC Med Genomics 4: 75.
27. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, et al. (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486: 405-409.
28. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
29. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, et al. (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486: 353-360.
30. Shah SP, Roth A, Goya R, Oloumi A, Ha G, et al. (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486: 395-399.
31. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, et al. (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 20486: 400-404.
32. Tran B and Bédard PL (2011) Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 13: 221.
33. van Agthoven T, Sieuwerts AM, Veldscholte J, Meijer-van Gelder ME, et al. (2009) CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer. Br J Cancer 2009; 101:1824-1832.
34. Karn T, Ruckhäberle E, Hanker L, Müller V, Schmidt M, et al. (2011) Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance. Breast Cancer Res Treat 130: 409-420.
35. van Agthoven T, Godinho MF, Wulfkuhle JD, Petricoin EF 3rd, Dorssers LC (2012) Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines. Int J Cancer 131: 1998-2007.
36. Dadi S, Le Noir S, Payet-Bornet D, Lhermitte L, Zacarias-Cabeza J, et al. (2012) TLX homeodomain oncogenes mediate T cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRa gene expression. Cancer Cell 21:563-576.
37. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, et al. (1995) A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A 92: 3963-3967.
38. Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, et al. (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med:e90.
39. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100: 229-235. (Pubitemid 44631925)
40. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, et al. (2009) Circos: an information aesthetic for comparative genomics. Genome Res 19: 1639-1645.
41. Deng N, Goh LK, Wang H, Das K, Tao J, et al. (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61:673-684.
42. Yeang CH, McCormick F, Levine A (2008) Combinatorial patterns of somatic gene mutations in cancer. Faseb J 22: 2605-2622
43. Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani B (2013) Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov 12: 35-50.
44. Bergamaschi A, Christensen BL, Katzenellenbogen BS (2011) Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis. Breast Cancer Res 13: R70.
45. Bernard-Pierrot I, Gruel N, Stransky N, Vincent-Salomon A, Reyal F, et al. (2008) Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res 68: 7165-7175.
46. Holland DG, Burleigh A, Git A, Goldgraben MA, Perez-Mancera PA, et al. (2011) ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med 3: 167-180.
47. Zhang J, Liu X, Datta A, Govindarajan K, Tam WL, et al. (2009) RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest 119: 2171-2183.
48. Braun L, Mietzsch F, Seibold P, Schneeweiss A, Schirmacher P, et al. (2013) Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss. Mod Pathol 26: 1161-1171.
49. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, et al. (2013) Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol 24: 661-668.
50. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167.
51. Weigelt B, Mackay A, A'hern R, Natrajan R, Tan DS, et al. (2010). Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 11: 339-349.
52. Fang H, Nie L, Chi Z, Liu J, Guo D, et al. (2013) RecQL4 Helicase Amplification Is Involved in Human Breast Tumorigenesis. PLoS One 8:e69600.
53. Cornen S, Adelaide J, Bertucci F, Finetti P, A Guille A., et al. (2012) Mutations and deletions of ARID1A in breast tumors. Oncogene 31: 4255-4256.
54. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, et al. (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70: 2085-2094.
55. Kwek SS, Roy R, Zhou H, Climent J, Martinez-Climent JA, et al. (2009) Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. Oncogene 28:1892-1903.
56. Karlsson E, Waltersson MA, Bostner J, Pérez-Tenorio G, Olsson B, et al. (2011) High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Genes Chromosomes Cancer 50: 775-787.
57. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer (2013). Mitelman F, Johansson B and Mertens F (Eds.), http://cgap.nci.nih.gov/ Chromosomes/Mitelman.Accessed 2013 Dec 6.
58. Teh MT, Gemenetzidis E, Patel D, Tariq R, Nadir A, et al. (2012) FOXM1 induces a global methylation signature that mimics the cancer epigenome in head and neck squamous cell carcinoma. PLoS One 2012; 7: e34329.
59. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. (2006) miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res.34 (Database issue): D140-144. miRBase is available at http://microrna. sanger.ac.uk/.
60. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, et al. (2006) RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66: 6512-6520. (Pubitemid 44085605)
61. Huang B, Qu Z, Ong CW, Tsang YH, Xiao G, et al. (2012) RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor α. Oncogene 31: 527-534.
62. Accili D, Arden KC (2004) FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117 : 421-426. (Pubitemid 38610228)
63. Zou Y, Tsai W-B, Cheng C-J, Hsu C, Chung YM, et al. (2008) Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. Breast Cancer Research 10: R21.
64. Habashy HO, Rakha EA, Aleskandarany M, Ahmed MAH, Green AR, et al. (2011) FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. Breast Cancer Research and Treatment 129: 11-21.
65. Knight 3rd WA, Osborne CK, Yochmowitz MG, McGuire WL (1980) Steroid hormone receptors in the management of human breast cancer, Ann Clin Res 12: 202-207. (Pubitemid 11179131)
66. Ignatiadis M, Sotiriou C (2013) Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol 10: 494-506.
67. Koo CY, Muir KW, Lam EW (2012) FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta 1819: 28-37.
68. Wang M, Gartel AL (2011) Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts. Mol Cancer Ther 10: 2287-2297.